Screener
Assembly Biosciences ASMB Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Assembly Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211987
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $31,120 | $58,450 |
| Marketable securities | 195,481 | 189,656 |
| Accounts receivable from collaboration with a related party | 451 | 974 |
| Prepaid expenses and other current assets | 5,561 | 5,469 |
| Total current assets | 232,613 | 254,549 |
| Property and equipment, net | 214 | 221 |
Item 1. Financial Statements
FAQ
- What is Assembly Biosciences's short-term investments?
- Assembly Biosciences (ASMB) reported short-term investments of $195.48M in Q1 2026.
- How has Assembly Biosciences's short-term investments changed year-over-year?
- Assembly Biosciences's short-term investments increased by 189.1% year-over-year, from $67.62M to $195.48M.
- What is the long-term trend for Assembly Biosciences's short-term investments?
- Over 5 years (2020 to 2025), Assembly Biosciences's short-term investments has grown at a 3.9% compound annual growth rate (CAGR), from $156.97M to $189.66M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Assembly Biosciences's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude